Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy

  • Read more about Bone Therapeutics publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy

Bone Therapeutics secures up to €16M loan financing from the EIB to accelerate clinical and commercial development of innovative orthopedic treatments

  • Read more about Bone Therapeutics secures up to €16M loan financing from the EIB to accelerate clinical and commercial development of innovative orthopedic treatments

Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 5 August 2021

  • Read more about Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 5 August 2021

Bone Therapeutics appoints Anne Leselbaum, MD as Chief Medical Officer

  • Read more about Bone Therapeutics appoints Anne Leselbaum, MD as Chief Medical Officer

Bone Therapeutics provides update on the progress of clinical studies

  • Read more about Bone Therapeutics provides update on the progress of clinical studies

Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

  • Read more about Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 23 August 2021

  • Read more about Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 23 August 2021

Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank

  • Read more about Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank

Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004

  • Read more about Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004

Bone Therapeutics reacts to the press release issued by Hybrigenics

  • Read more about Bone Therapeutics reacts to the press release issued by Hybrigenics

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions